Scrutinizing the landscape of DNA methylation epigenetic face(s) in glioblastomas

Abstract

Among several types of malignancies, glioblastoma multiforme (GBM) is considered one of the most devastating brain tumors. GBM has a poor prognosis, with less than 15 months overall survival, despite different conventional therapies. Studying different epigenetic modalities that, eventually, lead to this type of aggressive malignancy is crucial and will add significant value for better diagnosis, prognosis, and discovery of potential targeted biological sites. Despite the heritability of these alterations, they are currently considered pivotal therapeutic targets. Elucidating epigenetic changes in brain tumors that led to gene silencing, such as aberrant CpG island promoter DNA hypermethylation and histone deacetylation, will likely improve our understanding of GBM molecular etiology and would provide new novel potential treatment modality option(s), to emerge in the era of molecular epigenetic therapies, especially possible potential novel natural compounds.